Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat autoimmune disorders due to the cytokine’s preferential expansion of immunosuppressive regulatory T cells (Tregs). However, off-target immune cell activation and short serum half-life limit the clinical potential of IL-2 trea...

Descripción completa

Detalles Bibliográficos
Autores principales: VanDyke, Derek, Iglesias, Marcos, Tomala, Jakub, Young, Arabella, Smith, Jennifer, Perry, Joseph A., Gebara, Edward, Cross, Amy R., Cheung, Laurene S., Dykema, Arbor G., Orcutt-Jahns, Brian T., Henclová, Tereza, Golias, Jaroslav, Balolong, Jared, Tomasovic, Luke M., Funda, David, Meyer, Aaron S., Pardoll, Drew M., Hester, Joanna, Issa, Fadi, Hunter, Christopher A., Anderson, Mark S., Bluestone, Jeffrey A., Raimondi, Giorgio, Spangler, Jamie B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631798/
https://www.ncbi.nlm.nih.gov/pubmed/36261022
http://dx.doi.org/10.1016/j.celrep.2022.111478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631798/
https://www.ncbi.nlm.nih.gov/pubmed/36261022
http://dx.doi.org/10.1016/j.celrep.2022.111478

Ejemplares similares